Guest: Everett E. Vokes, MD 


In this Grand Rounds recorded live at ASCO, Dr. Vokes introduces the concept of T-cell blockade and Checkpoint Inhibition as rationale for considering use of anti-PD-1 anti-CTLA-4 agents in the management of non-small cell lung cancer (NSCLC). Also discussed will be data reflective of the use of tumor biomarkers when selecting treatment strategies for patients with NSCLC, specifically those with elevated expression of PD-L1.

Immunotherapy for Non-small Cell Lung Cancer: A Brief Review

Grand Rounds, a staple of American medical education for more than 100 years, spans every field of clinical practice. It is a master class on the art and science of medicine, delivered by renowned clinicians in academic settings nationwide. Yet in today's practice, where time is an all-too precious commodity, regular attendance at Grand Rounds sessions has become increasingly difficult. In response to this challenge, ReachMD brings the lecture hall to you, with these outstanding talks from top academic centers across the country.

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Health

Alternative Health

Self-Help

Sexuality

Fitness & Nutrition

Guest: Charles E. Miller, MD, FACOG 



  Whenever the topic of establishing minimally invasive hysteroscopic surgery in the office setting comes up, many physicians ask why and how. Leveraging decades of professional experience, this activity answers those questions by reviewing the necessary training and staff requirements, the procedures that are most beneficial for your patients, the path to accruing a patient and referral base, and most importantly, maintaining patient safety while ensuring pain control with optimal outcomes.  

Establishing an In-Office Minimally Invasive Surgery Practice: Driving Better Patient and Practice Outcomes

Guest: Cynthia Gyamfi-Bannerman, MD, BSc, MSc 



  About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counseling regarding prenatal care and lifestyle changes. To download the algorithms mentioned in this activity, click here.1 1. McCue, B, Torbenson, VE. Fetal fibronectin: The benefits of a high negative predictive value in management of preterm labor.Contemp Ob Gyn. 2017;62(10)(suppl):1-6

Role of Fetal Fibronectin (fFN) in the Risk-Assessment for Preterm Birth (PTB)

Guest: Sagar Lonial, MD, FACP 



  The treatment armamentarium for multiple myeloma (MM) has expanded significantly in recent years, with 6 new agents or indications approved by the US Food & Drug Administration since 2015. Treatment options now include immunomodulatory drugs, proteasome inhibitors, a histone deacetylase inhibitor, and immunotherapies, making clinical decisions much more complex. Additionally, best practices and consensus guidelines, such as those from the National Comprehensive Cancer Network® (NCCN®) and International Myeloma Working Group (IMWG), are constantly evolving as new data are published. Approval of these new agents, revision of response criteria, and implementation of new approaches to risk assessment and monitoring residual disease are causing significant changes in the management of MM. This activity will review areas of current controversy and topics for which consensus is not yet established, including when to initiate treatment, determining transplant eligibility, high-risk disease, duration of maintenance therapy, sequencing newly approved drugs, and choice of treatment at relapse.

Clinical Debates in Multiple Myeloma: Putting Evidence Into Context

Guest: Scott Newsome, DO, MSCS, FAAN 


The complexity and heterogeneity of multiple sclerosis (MS) pathogenesis renders its clinical course and response to therapy highly variable, particularly among special populations. This includes patients considering pregnancy or minority patients. This necessitates optimal strategies to personalize therapy and monitor disease activity and progression in special populations. This educational activity will review cutting-edge research on the unique considerations for prognosis, monitoring, and treatment response in special populations of MS patients. Focused attention will be given to translating research into optimized therapeutic strategies tailored to patient-specific characteristics with the goal of slowing disease progression. A compelling case study will be presented to illustrate clinically relevant challenges in disease management. Fee Information &amp; Refund/Cancellation Policy:There is no fee for this educational activity. To download the slide handouts for this presentation, please click here.

Case Challenges in MS: Tailoring Therapy to Patient-Specific Characteristics

Guest: Martin R. Chavez, MD, FACOG 


About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counselling regarding prenatal care and lifestyle changes.

Immunotherapy for Non-small Cell Lung Cancer: A Brief Review

Download our free app to listen on your phone